DK3235812T3 - Deutererede derivater af ivacaftor - Google Patents
Deutererede derivater af ivacaftor Download PDFInfo
- Publication number
- DK3235812T3 DK3235812T3 DK17160386T DK17160386T DK3235812T3 DK 3235812 T3 DK3235812 T3 DK 3235812T3 DK 17160386 T DK17160386 T DK 17160386T DK 17160386 T DK17160386 T DK 17160386T DK 3235812 T3 DK3235812 T3 DK 3235812T3
- Authority
- DK
- Denmark
- Prior art keywords
- ivacaftor
- deuterated derivatives
- deuterated
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161487497P | 2011-05-18 | 2011-05-18 | |
EP12725197.3A EP2709986B1 (en) | 2011-05-18 | 2012-05-17 | Deuterated derivatives of ivacaftor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3235812T3 true DK3235812T3 (da) | 2019-11-25 |
Family
ID=46201810
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12725197.3T DK2709986T3 (da) | 2011-05-18 | 2012-05-17 | Deutererede derivater af ivacaftor |
DK17160386T DK3235812T3 (da) | 2011-05-18 | 2012-05-17 | Deutererede derivater af ivacaftor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12725197.3T DK2709986T3 (da) | 2011-05-18 | 2012-05-17 | Deutererede derivater af ivacaftor |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP3235812B1 (da) |
JP (2) | JP6063455B2 (da) |
AU (5) | AU2012255711B2 (da) |
BR (1) | BR112013029240B1 (da) |
CA (1) | CA2834574C (da) |
CY (2) | CY1119090T1 (da) |
DK (2) | DK2709986T3 (da) |
EA (1) | EA028378B1 (da) |
ES (2) | ES2628465T3 (da) |
HK (1) | HK1244183A1 (da) |
HR (2) | HRP20170754T1 (da) |
HU (1) | HUE032771T2 (da) |
LT (1) | LT2709986T (da) |
ME (2) | ME02749B (da) |
MX (1) | MX349159B (da) |
PL (2) | PL3235812T3 (da) |
PT (2) | PT2709986T (da) |
RS (2) | RS56096B1 (da) |
SI (2) | SI3235812T1 (da) |
WO (1) | WO2012158885A1 (da) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS60205B1 (sr) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
PL3235812T3 (pl) * | 2011-05-18 | 2020-04-30 | Vertex Pharmaceuticals (Europe) Limited | Deuterowane pochodne iwakaftoru |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
WO2013151758A2 (en) | 2012-04-06 | 2013-10-10 | The Uab Research Foundation | Methods for increasing cftr activity |
JP6146990B2 (ja) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたcftr増強物質 |
WO2014078842A1 (en) * | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
PL3203840T3 (pl) | 2014-10-06 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
BR112018005454A2 (pt) * | 2015-09-21 | 2018-10-09 | Vertex Pharmaceuticals Europe Ltd | administração de potencializadores de cftr deuterados |
MA42954A (fr) * | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals Europe Ltd | Potentialisateurs cftr deutérés |
MX2018012331A (es) * | 2016-04-07 | 2019-05-23 | Proteostasis Therapeutics Inc | Atomos de silicona que contienen analogos de ivacaftor. |
AU2017280206A1 (en) | 2016-06-21 | 2019-01-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
JP2017105824A (ja) * | 2017-02-10 | 2017-06-15 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたcftr増強物質 |
SG11202004264VA (en) | 2017-12-01 | 2020-06-29 | Vertex Pharma | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
JP6654223B2 (ja) * | 2018-08-13 | 2020-02-26 | バーテックス ファーマシューティカルズ (ヨーロッパ) リミテッド | 重水素化されたcftr増強物質 |
WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
EP4013759A1 (en) | 2019-08-14 | 2022-06-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2021030552A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
LV15575A (lv) | 2019-12-20 | 2021-06-20 | Latvijas Organiskās Sintēzes Institūts | Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
AU2021325923A1 (en) | 2020-08-13 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
CA3197857A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CA3197173A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225763A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20230374038A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076628A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225765A2 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20230365587A1 (en) | 2020-10-07 | 2023-11-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225446A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076629A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4259139A1 (en) | 2020-12-10 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
TW202333699A (zh) | 2022-02-03 | 2023-09-01 | 美商維泰克斯製藥公司 | 囊腫纖維化之治療方法 |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040068613A (ko) * | 1994-03-25 | 2004-07-31 | 이소테크니카 인코포레이티드 | 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물 |
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
JP4101661B2 (ja) | 2001-05-03 | 2008-06-18 | エフ.ホフマン−ラ ロシュ アーゲー | 非晶質メシル酸ネルフィナビルの製薬剤形 |
JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
LT2489659T (lt) | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Atp rišančios kasetės transporterių moduliatoriai |
CA2581169A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
WO2007075946A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
RS60205B1 (sr) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
CA2652072A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CA2698808A1 (en) * | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
ES2857152T3 (es) | 2008-08-13 | 2021-09-28 | Vertex Pharma | Composición farmacéutica y administraciones de la misma |
NZ591315A (en) * | 2008-09-03 | 2012-08-31 | Teva Pharma | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
PL3235812T3 (pl) * | 2011-05-18 | 2020-04-30 | Vertex Pharmaceuticals (Europe) Limited | Deuterowane pochodne iwakaftoru |
-
2012
- 2012-05-17 PL PL17160386T patent/PL3235812T3/pl unknown
- 2012-05-17 PT PT127251973T patent/PT2709986T/pt unknown
- 2012-05-17 RS RS20170601A patent/RS56096B1/sr unknown
- 2012-05-17 PT PT171603863T patent/PT3235812T/pt unknown
- 2012-05-17 CA CA2834574A patent/CA2834574C/en active Active
- 2012-05-17 EA EA201391615A patent/EA028378B1/ru unknown
- 2012-05-17 SI SI201231694T patent/SI3235812T1/sl unknown
- 2012-05-17 ES ES12725197.3T patent/ES2628465T3/es active Active
- 2012-05-17 BR BR112013029240-7A patent/BR112013029240B1/pt active IP Right Grant
- 2012-05-17 ME MEP-2017-112A patent/ME02749B/me unknown
- 2012-05-17 ES ES17160386T patent/ES2758028T3/es active Active
- 2012-05-17 RS RS20191494A patent/RS59744B1/sr unknown
- 2012-05-17 DK DK12725197.3T patent/DK2709986T3/da active
- 2012-05-17 DK DK17160386T patent/DK3235812T3/da active
- 2012-05-17 LT LTEP12725197.3T patent/LT2709986T/lt unknown
- 2012-05-17 WO PCT/US2012/038297 patent/WO2012158885A1/en active Application Filing
- 2012-05-17 EP EP17160386.3A patent/EP3235812B1/en active Active
- 2012-05-17 JP JP2014511524A patent/JP6063455B2/ja active Active
- 2012-05-17 PL PL12725197T patent/PL2709986T3/pl unknown
- 2012-05-17 MX MX2013013450A patent/MX349159B/es active IP Right Grant
- 2012-05-17 EP EP12725197.3A patent/EP2709986B1/en active Active
- 2012-05-17 SI SI201230988A patent/SI2709986T1/sl unknown
- 2012-05-17 HU HUE12725197A patent/HUE032771T2/en unknown
- 2012-05-17 ME MEP-2019-325A patent/ME03652B/me unknown
- 2012-05-17 AU AU2012255711A patent/AU2012255711B2/en active Active
-
2016
- 2016-12-16 JP JP2016243941A patent/JP2017078082A/ja active Pending
-
2017
- 2017-05-19 HR HRP20170754TT patent/HRP20170754T1/hr unknown
- 2017-06-02 CY CY20171100584T patent/CY1119090T1/el unknown
- 2017-07-27 AU AU2017208313A patent/AU2017208313A1/en not_active Abandoned
-
2018
- 2018-03-15 HK HK18103627.5A patent/HK1244183A1/zh unknown
-
2019
- 2019-08-28 AU AU2019222862A patent/AU2019222862B2/en active Active
- 2019-11-25 HR HRP20192114TT patent/HRP20192114T1/hr unknown
- 2019-12-04 CY CY20191101275T patent/CY1122498T1/el unknown
-
2021
- 2021-02-15 AU AU2021200970A patent/AU2021200970B2/en active Active
- 2021-06-08 AU AU2021203786A patent/AU2021203786B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3235812T3 (da) | Deutererede derivater af ivacaftor | |
DK2771364T3 (da) | Fremstilling af heterodimere proteiner | |
HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
CO6890099A2 (es) | Nuevos derivados dihidroquinolina-2-ona | |
DK3156056T3 (da) | Farmaceutiske sammensætninger der består af sorbitanestere | |
BR302012003140S1 (pt) | Configuração aplicada em relógio | |
UY4115Q (es) | Reloj | |
DK2733803T4 (da) | Sektion af kabelbakke | |
BR112014003878A2 (pt) | síntese de r-bifenilalaninol | |
BR112014013850A2 (pt) | conjunto de prateleiras | |
DK3494993T3 (da) | Ny anvendelse af maltotriosyl-transferase | |
DK2800572T3 (da) | Sammensætning af ellagitannin-rige ekstrakter | |
DK2692211T3 (da) | Lysdæmperstyring af vinkellysfordeling | |
DK2571843T3 (da) | Forbedret fremstilling af chalcon-derivater | |
DK2731572T3 (da) | Forbedringer af indgivelsesanordninger | |
DK2888228T3 (da) | Inhibitorer af CD40-TRAF6 interaktion | |
DK2838850T3 (da) | Oprensning af titantetrachlorid | |
DK2407155T3 (da) | Formuleringer af inecalcitol | |
DK2928896T3 (da) | Fast form af dihydro-pyrido-oxazin-derivat | |
DK2731573T3 (da) | Forbedringer af indgivelsesanordninger | |
IT1403977B1 (it) | Lunetta | |
IT1403991B1 (it) | Struttura perfezionata di stendibiancheria | |
UA22461S (uk) | Деталь фасонна компресійна-цанга | |
UA22462S (uk) | Деталь фасонна компресійна-фланець | |
UA23972S (uk) | Комплект етикеток |